Navigation Links
Confirmation of Strong Growth Over the First Half of 2008
Date:8/1/2008

Record Revenue of EUR1.55 Million (+45.5% at Constant Forex)

Substantial Increase in Sales of the JAK2 Test: +169%

LUMINY, France, August 1 /PRNewswire-FirstCall/ -- IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces its revenue for its first half to 30 June 2008.

(in thousands of 30 June 2007 30 June 2008 Variation Variation

euros)* at constant

forex

Revenue from products 879 1,415 +,61.2%

Revenue from services 218 137 -37.2%

Consolidated total 1,096 1,552 +41.6% + 45.6%

*non audited data, IFRS For the first half of 2008, revenue totaled EUR1.55 million versus EUR1.09 million for the same period of 2007, an increase of 45.5% at constant forex. At real currency rates, revenue growth was 41.6%.

Sales were up for IPSOGEN's entire portfolio of leukemia tests, but the JAK2 test recorded the most spectacular growth (+169%) despite the fact that this test only obtained CE certification towards the end of the period.

Vincent Fert, President and CEO, states: "We are very pleased with our achievements over this first half. The growth in activity was buoyant and in line with our expectations. These results confirm the potential of the JAK2 test in the diagnosis of myeloproliferative disorders and show that IPSOGEN's product portfolio is perfectly positioned to benefit from the molecular diagnosis of cancer market's very dynamic growth."

About IPSOGEN

IPSOGEN develops and markets molecular diagnostic assays for patients with cancer. With more than 60 products already used routinely in more than 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now also targeting breast cancer with the aim of providing diagnostic information that has been inaccessible until now. IPSOGEN intends to establish itself as a world leader in the molecular diagnosis of cancer. The company is pursuing the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society in general. IPSOGEN has a workforce of some 40 people in France and the United States.

Publication of results for the first half of 2008: 9 October 2008 (after market)


'/>"/>
SOURCE IPSOGEN
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
4. U-M research: New plastic is strong as steel, transparent
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Cephalon Announces Strong Third Quarter Financial Results
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Genoptix Reports Strong Financial Results For Third Quarter 2007
11. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):